Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7NJWY)

Drug Name

Spiroglumide Drug Info

Synonyms

UNII-EZS5V8UN4Y; 137795-35-8; EZS5V8UN4Y; CHEMBL283820; CR-2194; (4R)-5-(8-azaspiro[45]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid; (R)-gamma-(3,5-Dichlorobenzamido)-delta-oxo-8-azaspiro(45)decane-8-valeric acid; Spiroglumide [INN]; AC1Q3LYL; AC1L24DH; SCHEMBL7920324; CTK0H9697; DTXSID60160311; FJCZHMXAGBYXHJ-QGZVFWFLSA-N; BDBM50048772; (R)-5-(8-Aza-spiro[45]dec-8-yl)-4-(3,5-dichloro-benzoylamino)-5-oxo-pentanoic acid; Radaxafine HCl

Indication

Disease Entry	ICD 11	Status	REF
Stomach disease	DA43-DA4Y	Phase 2	[1]
Neuropathic pain	8E43.0	Discontinued in Phase 1	[2]

Cross-matching ID

PubChem CID: 65987
CAS Number: CAS 137795-35-8
TTD Drug ID: DM7NJWY

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[2]
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Antagonist	[3]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	5.618	5.638	5.466	6.002
Dopamine transporter (DAT)	DTT	SLC6A3	4	2.609	5.233	3.7
Norepinephrine transporter (NET)	DTT	SLC6A2	2.459	3.426	3.322	3.35

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Stomach disease

ICD Disease Classification

DA43-DA4Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine transporter (DAT)	DTT	SLC6A3	1.08E-03	-3.08	-1.99

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Progress medicinal chem PMC37H. Page(48).
2	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
3	Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.